Mansuo Shannon, Ph.D.

Dr. Shannon is a visionary drug hunter and seasoned pharmaceutical executive with over 18 years of experience at Bayer, Eli Lilly, Roche/Chugai, and Merck, and is recognized for her expertise in advancing breakthrough therapies spanning small molecules, biologics, and cutting-edge genetic medicines. She is the Chief Scientific Officer at AskBio, Bayer’s wholly owned gene therapy and gene editing subsidiary. Throughout her career, Mansuo has demonstrated a passion for tackling the most challenging disease indications, strategically targeting high-conviction biological pathways with optimal modalities. Her leadership has been instrumental in driving multiple programs into clinical development, most notably the Phase 2 proof-of-concept study for Zagotenemab in Alzheimer’s Disease. Dr. Shannon earned her Ph.D. in Molecular Biology from Princeton University and completed her postdoctoral fellowship at MIT under Nobel Laureate Dr. Susumu Tonegawa, grounding her executive leadership in rigorous science and visionary innovation.